

## New data for simeprevir will be presented at EASL's International Liver Congress™ 2017

**Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR)** today informs that new clinical data for simeprevir, an NS3/4A protease inhibitor for the treatment of hepatitis C virus infection, will be presented by our partner Janssen Sciences Ireland UC (Janssen) in conjunction with The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April.

A total of four presentations will be made, including one oral presentation. The presentations will cover preclinical and clinical data on the triple combination of simeprevir, odalasvir and AL-335, as well as data on the efficacy, safety and tolerability of simeprevir used as a component of various combination therapies in a number of different adult patient populations.

### Data presented at the International Liver Congress™ 2017 include:

#### Oral Presentation:

##### **Abstract PS-153**

Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis.

*Authors:* Ed Gane, Catherine Stedman, Matthew McClure, David Apelian, Chris Westland, Jennifer Vuong, Megha Patel, Thomas Kakuda, Sushmita Chanda, Lawrence Blatt, Leo Beigelman, David Smith, John Fry

#### Poster Presentations:

##### **Abstract FRI-276**

In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir.

*Authors:* Leen Vijgen, Bart Fevery, Andreas Jekle, Kenneth Shaw, Hua Tan, Oliver Lenz, Julian Symons, Sandra De Meyer

##### **Abstract THU-281**

Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies.

*Authors:* Fiona Marra, Christoph Höner zu Siederdissen, Saye Khoo, Markus Cornberg, Michael Schlag, Sivi Ouwerkerk-Mahadevan, Ceyhun Bicer, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer, David Back

##### **Abstract FRI-249**

Efficacy and safety of simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy.

*Authors:* John Dillon, Stefan Mauss, Catherine Nalpas, Ceyhun Bicer, Michael Schlag, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer

Details of all presentations for The International Liver Congress™ 2017 are available at: <http://www.easl.eu/>.

### For further information, please contact:

Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211

Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

---

### **About Medivir**

Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.